2024-10-07 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**1. Performance vs. S&P 500 (VOO)**

Abbott Laboratories is a healthcare company that develops, manufactures, and sells a wide range of pharmaceutical, diagnostic, nutritional, and medical device products. 

**Cumulative Return:**

* **ABT:** 101.67%
* **VOO (S&P 500):** 133.14%

**Lagging Performance:**

* **Current Lag:** -31.47%
* **Relative Lag:** 11.58% (This means ABT's performance is currently lagging behind VOO by 31.47%, and this lag is at the 11.58th percentile of its historical range.)

**2. Recent Price Movement**

* **Closing Price:** $112.64
* **5-Day Moving Average:** $113.22
* **20-Day Moving Average:** $114.67
* **60-Day Moving Average:** $110.79

**3. Technical Indicators**

* **RSI:** 28.11 (This suggests that ABT is currently in oversold territory.)
* **PPO:** -0.39 (This indicates that the price momentum is negative.)
* **Delta_Previous_Relative_Divergence:** -11.95 (Negative indicates a short-term downtrend.)
* **Expected Return:** 0.0% (This suggests that the stock is expected to perform in line with the S&P 500 over the next 5 years.)

**4. Recent Earnings and Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-31 | 0.74 | 10.38 B$ |
| 2024-05-02 | 0.7 | 9.96 B$ |
| 2023-11-01 | 0.82 | 10.14 B$ |
| 2023-08-03 | 0.79 | 9.98 B$ |
| 2024-07-31 | 0.79 | 9.98 B$ |

* The most recent earnings report for Q2 2024 showed EPS of $0.74, which beat analyst estimates by $0.04. Revenue came in at $10.38 billion, also exceeding expectations.
* The company continues to see strong demand for its products, particularly in the diagnostics and nutrition segments.
* However, ABT faces challenges from rising inflation and supply chain disruptions.

**5. News and Recent Issues**

* **Recent Market Outlook:** ABT's stock price has been relatively stable in recent months. Some analysts believe the company is well-positioned for growth in the long term, while others are concerned about the impact of inflation on its earnings.
* **Analyst Opinions:** The consensus among analysts is that ABT is a **Hold**, with a target price of $118.
* **Performance Highlights:** ABT has a strong track record of dividend growth and a high dividend yield. 

**6. Conclusion**

ABT has been lagging behind the S&P 500, with its current price showing a slight downtrend. While recent earnings have been positive, concerns about inflation and supply chain disruption remain. Technical indicators suggest oversold conditions, but the expected return is neutral compared to the S&P 500. Overall, the company's long-term prospects remain strong due to its diversified product portfolio and commitment to innovation. 

**7. Recommendations:**

* **Long-term investors:** Consider holding ABT stock for its potential growth and strong dividend yield.
* **Short-term traders:**  Consider waiting for a potential breakout from the current downtrend before entering a position.

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. It is essential to consult with a qualified financial advisor before making any investment decisions.
